Escitalopram in Patients With Social Anxiety Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00902226 |
Recruitment Status :
Completed
First Posted : May 15, 2009
Results First Posted : June 10, 2011
Last Update Posted : June 10, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Social Anxiety Disorder | Drug: Escitalopram | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | March 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Escitalopram |
Drug: Escitalopram
Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Other Name: Cipralex, Lexapro |
- Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I) [ Time Frame: baseline and 12 weeks ]The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
- Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-S) [ Time Frame: baseline and 12 weeks ]The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
- Percentage of Patients Who Responded to Escitalopram After 12 Weeks of Treatment Using CGI-I <= 2 [ Time Frame: baseline and 12 weeks ]The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
- Percentage of Patients Who Achieved Remission After 12 Weeks of Treatment Using CGI-S <= 2 [ Time Frame: baseline and 12 weeks ]The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
- Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Work [ Time Frame: baseline and 12 weeks ]The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.
- Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Family [ Time Frame: baseline and 12 weeks ]The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.
- Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Social [ Time Frame: baseline and 12 weeks ]The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The patient suffers from SAD, diagnosed according to ICD-10 (International Classification of Diseases)
- The patient meets criteria set in the national SPC for escitalopram
- The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs
Exclusion Criteria:
- The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10
- The patient has contraindications to escitalopram
- The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram
- The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance
- The patient is pregnant or breast-feeding
- The patient, if a woman of childbearing potential, is not using adequate contraception

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00902226
Russian Federation | |
RU001 | |
Moscow, Russian Federation |
Study Director: | Email contact viaH. Lundbeck A/S viaH. Lundbeck A/S | LundbeckClinicalTrials@lundbeck.com |
Responsible Party: | H. Lundbeck A/S |
ClinicalTrials.gov Identifier: | NCT00902226 History of Changes |
Other Study ID Numbers: |
12133A |
First Posted: | May 15, 2009 Key Record Dates |
Results First Posted: | June 10, 2011 |
Last Update Posted: | June 10, 2011 |
Last Verified: | May 2011 |
Social Anxiety Disorder SAD Antidepressant Anxiolytic |
Disease Anxiety Disorders Phobia, Social Pathologic Processes Mental Disorders Phobic Disorders Dexetimide Citalopram Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents |
Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Antiparkinson Agents Anti-Dyskinesia Agents Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |